(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 23.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.77%.
Biomarin Pharmaceutical's revenue in 2023 is $2,096,039,000.On average, 11 Wall Street analysts forecast BMRN's revenue for 2023 to be $498,472,434,268, with the lowest BMRN revenue forecast at $425,714,643,723, and the highest BMRN revenue forecast at $550,800,846,274. On average, 9 Wall Street analysts forecast BMRN's revenue for 2024 to be $601,603,079,769, with the lowest BMRN revenue forecast at $469,795,685,544, and the highest BMRN revenue forecast at $712,913,012,448.
In 2025, BMRN is forecast to generate $755,254,673,358 in revenue, with the lowest revenue forecast at $524,845,365,980 and the highest revenue forecast at $938,500,923,818.